VivoSeq
Other

Infectious Disease

23

Pipeline Programs↗

8

Active Trials↗

15

Companies Involved↗

Infectious Disease is an emerging landscape with 23 programs across 15 companies. The most active players are Appili Therapeutics Inc., Regeneron, Octapharma. 8 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

45/100

Completion Rate

86/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Appili Therapeutics Inc.

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1Octapharma logo

Octapharma

1 program

Phase 2J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

22 of 24 classified programs — the dominant modality here.

8%ALL OTHERSCell therapy28%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 97% of 29 pipeline programs.

Analysis

Trial Status

18

clinical trials

Recruiting6 · 33%
Completed6 · 33%
Unknown status3 · 17%
Not yet recruiting1 · 6%
Active, not recruiting1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

Real World Study of Classic Infectious Disease
Recruiting·HHuashan Hospital·N/A·NCT04020536·10,000 enrolled
Use of Teicoplanin on a Three-weekly Administration in the Infectious Diseases Unit
Recruiting·AAzienda Ospedaliera di Lecco·N/A·NCT06426212·40 enrolled
Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases
Recruiting·CCell Energy Life Sciences Group Co. LTD·Phase 1/2·NCT06416709·80 enrolled
Pathologies métaboliques et Infectieuses en Population générale à La Réunion : étude REUNION
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·N/A·NCT05400824·2,000 enrolled
An International Observational Study of Adults With Acute Infection
Recruiting·UUniversity of Minnesota·N/A·NCT07069400·1,500 enrolled
Genetic Susceptibility to Severe Infections Including in Particular But Not Exhaustively All Types of Viral, Bacterialn and Fungal Infections.
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·N/A·NCT06102070·2,000 enrolled
Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)
Active, not recruiting·—·N/A·NCT01758081·25,874 enrolled
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
Not yet recruiting·ZZhejiang University·Phase 1·NCT04657965·144 enrolled
Collection of Human Biological Samples for the Development and Validation of New Methods of Diagnosis and for the Realization of Expertises Diagnostics in the Field of Infectious Diseases and Tropical
Completed·IInstitut Pasteur·N/A·NCT03912246·800 enrolled
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
Completed·SSerum Life Science Europe GmbH·Phase 3·NCT04435379·2,038 enrolled
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Completed·Bayer logoBayer·Phase 3·NCT02625974·330 enrolled
Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02338986·10 enrolled
Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States
Completed·MMidway Specialty Care Center·N/A·NCT06393387·800 enrolled
Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach
Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·N/A·NCT05557539·249 enrolled
Antithrombin III in Infectious Disease Caused by COVID-19
Terminated·—·Phase 2·NCT04899232·52 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)